Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sab Biotherapeutics Inc (NQ: SABS )

2.840 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 2.840
Bid (Size) 1.180 (1)
Ask (Size) 3.610 (1)
Prev. Close 2.840
Today's Range 2.840 - 2.840
52wk Range 2.360 - 10.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
SAb Biotherapeutics Rebrands as SAB BIO
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-59.43%
-59.43%
1 Month
N/A
N/A
3 Month
-35.31%
-35.31%
6 Month
-51.12%
-51.12%
1 Year
-64.90%
-64.90%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Departure of Chief Financial Officer
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
Via InvestorPlace
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides SAB-142 Trial Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at INNODIA Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Announces Executive Leadership Change
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.